Total revenue for the year to end December came in at $1.97mln compared to $1.79mln in the same period of 2015.
Showing 25 of 1352
Revenues are on the rise and the group’s efforts to bring in new business is delivering.
CytomX will also be eligible to receive up to US$448mln in milestone payments, as well as royalty payments, if development, regulatory and sales targets are met.
Caladrius is selling out to the junior partner in the joint venture and trousering US$75mln
Shares in Hikma Pharmaceuticals have gained today after it reported a better-than-expected drop in full year profit
Editas is one of three companies currently locked in a courtroom battle over the ownership of the gene-editing technique CRISPR
Billionaire investor Bill Ackman, via Pershing Square Capital Management, has retreated out of the drugmaker.
THC is expecting net profit of over $1 million in 2017.
VolitionRx Limited's senior management team will ring the closing bell at the New York Stock Exchange (NYSE) 1600 EDT
The broker Rodman looked at VolitionRx;s results and the potential ahead
2016 was a busy one for the diagnostic tests developer and 2017 looks set to be just as hectic
VolitionRx Limited said on Wednesday it will present at the 29th Annual ROTH Conference being held March 12-15 in Dana Point, California
“2016 was an historic year for Profound in its journey to establish TULSA-PRO system as a new therapeutic standard in prostate cancer,” said Dr Arun Menawat, the chief executive.
Denmark has one of the most advanced healthcare systems in the world and a reputation for innovation
The company shed four-fifths of its market value over the last year after a string of profit warnings and earnings restatements
VolitionRx has presented data at the World Congress of GI Endoscopy 2017 conference in Hyderabad, India, from a study that confirms prior test results that the Nu.QTM Colorectal Cancer Screening Triage test reduces the total number of colonoscopy referrals while maintaining high sensitivity for cancer detection
Marapharm is advancing operations in Canada and the United States
Pharmaxis' partner has funded US$22 million of the expected US$26 million trial cost.
A PRV entitles the holder to a priority review of a single New Drug Application or Biologics License Application
Aviragen says its trial of asthma treatment vapendavir has failed to meet its primary endpoint.
Pharmaceutical group Allergan has announced the acquisition of Zeltiq Aesthetics for $2.475bn to gain access to its body contouring technology.
"The preliminary findings suggesting the potential triglyceride-lowering activity of VK2809 in GSD Ia are encouraging," said Professor Dwight Koeberl of Duke University School of Medicine.
The FTSE 100-listed firm posted trading profits of US$1.020bn for 2016, down 7% from 2015’s US$1.099bn, on revenue 1% higher at US$4.67bn.
Pressure BioSciences shares advanced by 6% on Thursday after the company said it had achieved CE Marking for the Barocycler 2320EXTREME, the company's recently-released, next-generation PCT-based sample preparation instrument, and has the green light to sell in Europe
The medical products firm saw its earnings rise by 19% to US$243mln, or 44 US cents a share, up from US$205mln, or 37 US cents a share at the same stage a year earlier.